Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma

Faridvand, Yousef; Oskuyi, Ali Eishi; Khadem-Ansari, Mohammad Hassan

doi:10.1179/1351000215y.0000000034

Cited by 13 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated levels of 8-OHdG with increase in serum nitrate and nitrite levels may be related with reduction in antioxidant defense system. The results of the present study are in accordance with previous studies, which mentioned the impairment of the anti-oxidant enzymes in MM disease (38). This reduction may be associated with silencing several genes related with the expression of antioxidant genes.…”

Section: Discussionsupporting

confidence: 82%

Elevated Serum 8-Hydroxy-2’-Deoxyguanosine, Nitrite, and Nitrate in Patients with Stage I Multiple Myeloma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Reactive oxygen species are highly active intermediates, which lead to cellular damage during imbalance between oxidative stress/antioxidant towards oxidative stress. Free radicals have been proposed to have a crucial role in development and progression of human cancer. Objectives: The main aim of this study was to assess the changes in 8-hydroxy-deoxyguanosine (8-OHdG), nitrite (NO2-), and nitrate (NO3-) levels in patients with Stage I multiple myeloma (MM). Methods: The serum samples were obtained from 34 patients with stage I MM (22 males and 12 females at stage I) who were matched with healthy control group. Total serum of NO2-and NO3-levels, in addition to serum 8-OHdG levels, were assayed by using the commercial assay kit.

show abstract

Section: Discussionsupporting

confidence: 82%

Elevated Serum 8-Hydroxy-2’-Deoxyguanosine, Nitrite, and Nitrate in Patients with Stage I Multiple Myeloma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The number in the affected and control groups represents the number of people tested. Data for this figure was extracted from references [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94], [95], [96], [97], [98], [99], [100], [101], [102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112], [113], [114], [115], [116], [117], [118], …”

Section: Figmentioning

confidence: 99%

Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

The notion that oxidative stress plays a role in virtually every human disease and environmental exposure has become ingrained in everyday knowledge. However, mounting evidence regarding the lack of specificity of biomarkers traditionally used as indicators of oxidative stress in human disease and exposures now necessitates re-evaluation. To prioritize these re-evaluations, published literature was comprehensively analyzed in a meta-analysis to quantitatively classify the levels of systemic oxidative damage across human disease and in response to environmental exposures.In this meta-analysis, the F2-isoprostane, 8-iso-PGF2α, was specifically chosen as the representative marker of oxidative damage. To combine published values across measurement methods and specimens, the standardized mean differences (Hedges’ g) in 8-iso-PGF2α levels between affected and control populations were calculated.The meta-analysis resulted in a classification of oxidative damage levels as measured by 8-iso-PGF2α across 50 human health outcomes and exposures from 242 distinct publications. Relatively small increases in 8-iso-PGF2α levels (g<0.8) were found in the following conditions: hypertension (g=0.4), metabolic syndrome (g=0.5), asthma (g=0.4), and tobacco smoking (g=0.7). In contrast, large increases in 8-iso-PGF2α levels were observed in pathologies of the kidney, e.g., chronic renal insufficiency (g=1.9), obstructive sleep apnoea (g=1.1), and pre-eclampsia (g=1.1), as well as respiratory tract disorders, e.g., cystic fibrosis (g=2.3).In conclusion, we have established a quantitative classification for the level of 8-iso-PGF2α generation in different human pathologies and exposures based on a comprehensive meta-analysis of published data. This analysis provides knowledge on the true involvement of oxidative damage across human health outcomes as well as utilizes past research to prioritize those conditions requiring further scrutiny on the mechanisms of biomarker generation.

show abstract

“…Estimated serum levels of antioxidants such as superoxide dismutase (SOD1), glutathione peroxidase, catalase and vitamins C and E were lower, whereas serum levels of oxidative stress markers (including malondialdehyd and advanced oxidation protein products) were higher in multiple myeloma patients compared to healthy individuals [38-42]. Accordingly, activities of antioxidants preventing lipid peroxidation such as paraoxonase (PON1) and arylesterase (ARE) were lower in multiple myeloma patient sera [43,44]. Levels of 8-isoprostane, a product of fatty acid peroxidation, were on the contrary higher in multiple myeloma patients [43].…”

Section: Oxidative Stressmentioning

confidence: 99%

“…Accordingly, activities of antioxidants preventing lipid peroxidation such as paraoxonase (PON1) and arylesterase (ARE) were lower in multiple myeloma patient sera [43,44]. Levels of 8-isoprostane, a product of fatty acid peroxidation, were on the contrary higher in multiple myeloma patients [43]. Moreover, decreased activities of ARE and PON1 were proposed as poor prognosis markers for a subgroup of multiple myeloma patients [44].…”

Section: Oxidative Stressmentioning

confidence: 99%

Oxidative stress and proteasome inhibitors in multiple myeloma

Lipchick

Fink

Nikiforov

2016

Pharmacological Research

View full text Add to dashboard Cite

Multiple myeloma is a form of plasma cell neoplasm that accounts for approximately 10% of all hematological malignancies. Recently, several novel drugs have been discovered that almost doubled the overall survival of multiple myeloma patients. One of these drugs, the first-in-class proteasome inhibitor bortezomib (Velcade) has demonstrated remarkable response rates in multiple myeloma patients, and yet, currently this disease remains incurable. The major factor undermining the success of multiple myeloma treatment is a rapidly emerging resistance to the available therapy. Thus, the development of stand-alone or adjuvant anti-myeloma agents becomes of paramount importance. Overproduction of intracellular reactive oxygen species (ROS) often accompanies malignant transformation due to oncogene activation and/or enhanced metabolism in tumor cells. As a result, these cells possess higher levels of ROS and lower levels of antioxidant molecules compared to their normal counterparts. Unbalanced production of ROS leads to oxidative stress which, if left unchecked, could be toxic for the cell. In multiple myeloma cells where high rates of immunoglobulin synthesis is an additional factor contributing to overproduction of ROS, further induction of oxidative stress can be an effective strategy to cope with this disease. Here we will review the available data on the role of oxidative stress in the cytotoxicity of proteasome inhibitors and the use of ROS-inducing compounds as anti-myeloma agents.

show abstract

Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma

Cited by 13 publications

References 27 publications

Elevated Serum 8-Hydroxy-2’-Deoxyguanosine, Nitrite, and Nitrate in Patients with Stage I Multiple Myeloma

Elevated Serum 8-Hydroxy-2’-Deoxyguanosine, Nitrite, and Nitrate in Patients with Stage I Multiple Myeloma

Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis

Oxidative stress and proteasome inhibitors in multiple myeloma

Contact Info

Product

Resources

About